NASDAQ: SPTXSeaport Therapeutics Inc Stock
$19.84
Updated May 1, 2026
SPTX Price
$19.84
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$19.50
52 Week High
$23.00
P/E
-0.63x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$74.88M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.18
Operating Cash Flow
-$78M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPTX Overview
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPTX's potential to beat the market
- SPTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SPTX news, forecast changes, insider trades & much more!
SPTX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SPTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SPTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SPTX due diligence checks available for Premium users.
Valuation
SPTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.63x
Industry
29.05x
Market
18.83x
SPTX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SPTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$249.0M
Liabilities
$16.2M
Debt to equity
-0.18
SPTX's short-term assets ($223.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPTX's short-term assets ($223.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SPTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Seaport Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.